Equity Profile

BBIO

BridgeBio Pharma, Inc.

Health CareBiotechnology$16.3B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to scale and sustain its operations, especially in the competitive biotech industry.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers. With a market cap of $16 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In the last quarter, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding pipeline updates.

Expectations

Wall Street Expectations

Overall expectations for BridgeBio's upcoming earnings are cautious, given the recent history of EPS misses. Investors are looking for any signs of improvement in revenue and pipeline advancements.

Bull Case

If the company can demonstrate progress in its clinical trials and provide positive updates on its pipeline, it could lead to a strong rebound in stock performance.

Bear Case

Continued misses on EPS and lack of clarity on revenue growth could further dampen investor sentiment and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of clinical trials for key therapies?

Investors will be looking for concrete evidence of advancement in the pipeline, which is critical for future revenue potential.

How does management plan to address the recent EPS misses and improve financial performance moving forward?

Understanding the company's strategy to enhance profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio's pipeline advancements, which could lead to unexpected positive results this quarter.

Supporting Evidence

The recent insider buying activity suggests confidence in the company's future prospects.

Options pricing indicates a lower expected move compared to historical averages, which may not reflect the potential upside.

The company's commitment to improving operational efficiency could yield better-than-expected results.

Key Risk

If clinical trial updates show significant progress, it could challenge the consensus view and lead to a positive revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its financial performance and advance its clinical pipeline.

Bull Confirmed If

Demonstrating significant progress in clinical trials with at least one therapy moving to the next stage could confirm the bull case.

Bear Confirmed If

Continued EPS misses and lack of clarity on revenue growth would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move of 1.75%, suggesting that traders expect limited volatility around the earnings report.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests a potential average one-day move of +1.48%, confirming a positive outlook on its pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss on earnings could lead to a decline, with history suggesting an average one-day move of +1.48% after misses, indicating potential investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Management's strategy for addressing recent EPS misses.
3Any commentary on operational efficiency improvements.
4Insights into revenue growth expectations for the upcoming quarters.
5Details on any new partnerships or collaborations in the pipeline.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to scale and sustain its operations, especially in the competitive biotech industry.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BBIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In the last quarter, BridgeBio reported an EPS of -$0.84, missing estimates by 19.32%. The stock reacted negatively, dropping 0.94% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding pipeline updates.

Expectations

Wall Street Expectations

Overall expectations for BridgeBio's upcoming earnings are cautious, given the recent history of EPS misses. Investors are looking for any signs of improvement in revenue and pipeline advancements.

Bull Case

If the company can demonstrate progress in its clinical trials and provide positive updates on its pipeline, it could lead to a strong rebound in stock performance.

Bear Case

Continued misses on EPS and lack of clarity on revenue growth could further dampen investor sentiment and lead to a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on the progress of clinical trials for key therapies?

Investors will be looking for concrete evidence of advancement in the pipeline, which is critical for future revenue potential.

How does management plan to address the recent EPS misses and improve financial performance moving forward?

Understanding the company's strategy to enhance profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio's pipeline advancements, which could lead to unexpected positive results this quarter.

Supporting Evidence

The recent insider buying activity suggests confidence in the company's future prospects.

Options pricing indicates a lower expected move compared to historical averages, which may not reflect the potential upside.

The company's commitment to improving operational efficiency could yield better-than-expected results.

Key Risk

If clinical trial updates show significant progress, it could challenge the consensus view and lead to a positive revaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its financial performance and advance its clinical pipeline.

Bull Confirmed If

Demonstrating significant progress in clinical trials with at least one therapy moving to the next stage could confirm the bull case.

Bear Confirmed If

Continued EPS misses and lack of clarity on revenue growth would solidify the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±1.75%

Historical Avg

±2.2%

Pricing cheap

The options market is pricing in a modest move of 1.75%, suggesting that traders expect limited volatility around the earnings report.

Options are pricing ±1.8% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.5%

30d HV

41.9%

Calls (144K)P/C Ratio: 0.38Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing cheap setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests a potential average one-day move of +1.48%, confirming a positive outlook on its pipeline.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A miss on earnings could lead to a decline, with history suggesting an average one-day move of +1.48% after misses, indicating potential investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key therapies.
2Management's strategy for addressing recent EPS misses.
3Any commentary on operational efficiency improvements.
4Insights into revenue growth expectations for the upcoming quarters.
5Details on any new partnerships or collaborations in the pipeline.